updat abbott eurofin roch covid-
brief connect seri follow recent announc abbott roch
eurofin develop serolog test determin past infect
view abbott roch key player proven track record test
develop widespread global distribut abil suppli quickli scale
eurofin deliv immedi track record much limit scale test
april announc launch igg test third covid-
test lab-bas serolog blood test detect antibodi igg
identifi person novel coronaviru april roch
announc develop elecsi serolog test
compani plan avail earli may countri accept ce mark activ
work fda emerg use author also april eurofin
announc launch multipl ce market serolog product test
antibodi avail immedi
serolog antibodi test critic assist understand immun
view major step potenti remov social
isolation/lock down countri across world serolog test aim establish
individu previous expos viru coronaviru
detect antibodi indic individu built immun viru
critic help us understand widespread infect therefor
like suscept popul area futur infect antibodi test
also prove use identif elig donor convalesc plasma
develop anti therapeut vaccin last week march
cdc began initi serolog studi serum sampl collect state
washington new york citi use in-hous develop laboratori test cdc
studi expand area studi region higher number diagnos
import measur igm igg antibodi igm antibodi first
line defens produc quickli day infect bodi take
longer produc igg antibodi key long-term immun
immunolog memori initi day follow infect antibodi level may
detect level limit feasibl window test individu may
take longer develop antibodi weekend epidemiologist state
yet evid posit serolog test demonstr immun
protect reinfect case appar reinfect quickli
patient previous test posit infect given known unreli
test yet appear reliabl data show confirm case re-
infect view potenti re-infect one import unansw
question diseas also around long enough
understand level antibodi requir provid protect long
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
roch deliv high double-digit million serolog test june compani
scale product fast possibl understand roch reagent
suppli capac unlik bottleneck test test
announc major diagnost supplier thu far view roch highest
roch test high throughput tests/hour immunoassay run
roch coba analys platform understand instal
lab global vari sizes/capac test take minut produc
result sampl need taken central machin compar
tests/hour abbot assay eurofin assay
opportun grow roch diagnost share us roch current serum
work area swa market share us global share recent
roch sell side virtual breakfast alan hipp cfo highlight opportun grow us
diagnost given claim broadest assay menu strong posit public
roch develop autom test initi detect activ infect roch see
opportun growth centralis point care test market
roch report result wed april expect hear
potenti ramp covid test molecular serolog like
quantif regard reduct demand routin test due disrupt
healthcar system caus lower doctor patient interact pandem
calcul roch add potenti sale covid serolog test alon could
produc revenu could see
uplift cse ep rise ep assum roch ramp
suppli serolog tests/month june decemb continu suppli
demand test/month assum price
oper margin oper margin view
reagent/test capabl bottleneck test roch coba
platform instal global capac rang tests/hour assum
would take capac month import short-term off-set
observ declin routin diagnost test quest report declin
end free short term capac test exercis
concentr antibodi test suspect sustain busi
opportun signific number test need potenti conjunct
avail vaccin
abbott eurofin also launch serolog test last week abbott sars-
igg test launch last week without eua abbott plan file
eua submiss fda also plan ce eu eurofin launch
separ test igg iga igm antibodi ce mark expect
market plenti space player given global demand test compar
test roch appear highest suppli volum highest throughput although
understand vari base upon platform technolog coba platform roch
architect platform abbott figur comparison test
note abbott current launch assay test igg roch
eurofin assay also test igm may abl identifi past covid infect patient
faster post symptom understand roch assay demonstr
sensit specif sampl day infect abbott current test
indic individu day post symptom howev abbott also develop
separ igm test expect come week
abbott confirm price molecular rapid test
approv last month new antibodi test approv last week
expect similar price upcom second antibodi later flow test expect
follow week recent abbot note follow result
med-tech team rais estim primarili driven test
molecular serolog would expect roch price competit use test
tri drive broad adopt coba platform us
abbott suppli test direct laboratori custom highlight abbott
sell diagnost directli warehous limit use wholesalers/distributor
make weekli shipment test avoid suppli chain interruption/hoard test
know whether roch depart normal distribut rout
point care serolog test also develop addit lab test
process train technician mention report understand roch
abbott develop point care serolog test allow signific scale
test allow effect near real time test howev timelin
develop disclos point care test bedsid test exampl
blood glucos monitors/hom pregnanc test end march becton
dickinson bd announc avail rapid serolog point care test
collabor biomedom small privat us clinic diagnost compani whilst
one first serolog test larg intern diagnost player
note bd capac suppli test compani month
test distribut healthcar provid us
fda review requir use covid serolog diagnost us fda issu
polici march allow certain serolog test market without prior fda review
enabl earli patient access test date fda grant emerg use
author eua one serolog test cellex igg/igm test
howev expect capac limit sinc cellex small privat compani
current fda list diagnost show manufactur lab
serolog test weekend fda put statement highlight
limit test warn healthcar provid use test result
sole basi diagnos past infect
figur compar tabl serolog test roch abbott eurofin
rocheabbotteurofinsbecton dickinsondiagnost revenu proport group testshigh double-digit million test june million april million ship million june million come maylaunch april without fda eua pathway launch april ce-ivd mark launch march ship aprilantibodi detectedigg igmigg onlyigg iga igmigg igmsensitivityest limit limit detailstest result minsrun coba instrument instal globallyind test day post symptomsrun architect instrument us labsthre separ test antibodi ce markpoint care testtest result minutesdistribut henri charl martineau univers toronto april
compani mention price
trung huynh domin lunn elizabeth walton jo walton matthew weston phd vik chopra certifi respect compani
secur individu analyz view express report accur reflect person view
subject compani secur part compens directli indirectli relat specif
recommend view express report
price rate histori abt
signifi initi assumpt coverag
price rate histori eurofin scient eufi pa
signifi initi assumpt coverag
price rate histori roch rog
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun octob canadian well europea exclud turkey rate
base stock total return rel analyst coverag univers consist compani cover alyst within relev sector
outperform repres attract neutral less attract und erperform least attract invest opportun latin america
turkey asia exclud japan australia stock rate base stock total return rel averag tal return relev countri
region benchmark india bse sensex index prior octob canadian rate base stock absolut total return
potenti current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may rang outperform
under-perform rate overlap neutral threshold oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cov er multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral nd under-perform close
